Company intelligence / Profile preview

R-OPRA

Ownership: Private
Development stage: Other

Overview

R-OPRA is a biotechnology company focused on developing innovative treatments for opioid use disorder and overdose. The company's lead candidate is a novel small molecule designed to act as a reversible opioid receptor antagonist, potentially offering a safer and more effective alternative to current treatments like naloxone. By leveraging unique pharmacological properties, R-OPRA aims to address the critical unmet needs in the opioid crisis. The company is currently in the pre-clinical stage, conducting studies to support future clinical development.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on R-OPRA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R-OPRA.

Explore the full profile